Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Arlen

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancerWilliam L Dahut, Charity Scripture, Edwin Posadas, et al.
Frontiers in Oncology|July 9, 2020
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian CancerKristen P Zeligs, Maria Pia Morelli, Justin M David, et al.
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.
The Journal of Urology|August 21, 2007
Clinical safety of a viral vector based prostate cancer vaccine strategyPhilip M Arlen, Lisa Skarupa, Mary Pazdur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaJames L Gulley, Philip M Arlen, Kwong-Yok Tsang, et al.
European Urology Oncology|October 20, 2023
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with EnzalutamideShruti U Gandhy, Fatima H Karzai, Marijo Bilusic, et al.
JAMA Oncology|August 21, 2015
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical TrialChristopher R Heery, Nuhad K Ibrahim, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2011
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancerMahsa Mohebtash, Kwong-Yok Tsang, Ravi A Madan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerYang-Min Ning, James L Gulley, Philip M Arlen, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancerWilliam L Dahut, Charity Scripture, Edwin Posadas, et al.
Frontiers in Oncology|July 9, 2020
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian CancerKristen P Zeligs, Maria Pia Morelli, Justin M David, et al.
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.
The Journal of Urology|August 21, 2007
Clinical safety of a viral vector based prostate cancer vaccine strategyPhilip M Arlen, Lisa Skarupa, Mary Pazdur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaJames L Gulley, Philip M Arlen, Kwong-Yok Tsang, et al.
European Urology Oncology|October 20, 2023
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with EnzalutamideShruti U Gandhy, Fatima H Karzai, Marijo Bilusic, et al.
JAMA Oncology|August 21, 2015
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical TrialChristopher R Heery, Nuhad K Ibrahim, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2011
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancerMahsa Mohebtash, Kwong-Yok Tsang, Ravi A Madan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerYang-Min Ning, James L Gulley, Philip M Arlen, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Pageof 9